A Phase III, Randomized, Open-Label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (sac-TMT, MK-2870) as a Monotherapy and in Combination with Pembrolizumab (MK-3475) versus Treatment of Physicians Choice in Participants with Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD L1 at CPS Less than 10 (TroFuse-11)
Clinical Trial Information
Trial Contact: Clinical Trial Referral Office
Trial Phone: 321-841-7246
Principal Investigator: Ana Cuesta Fernandez, MD
Phase: III
Age Group: ADULTOLDER_ADULT
ClinicalTrials.gov ID: NCT06841354
Objective
This study is designed to learn how well a new medicine, sac-TMT, alone or combined with pembrolizumab, treats a specific form of breast cancer compared with standard chemotherapy, and to understand the safety and side effects of these treatments.